# Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

> **NCT00621036** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Lymphoproliferative Disorder
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** autologous immunoglobulin idiotype-KLH conjugate vaccine
- **BIOLOGICAL:** sargramostim
- **DRUG:** methotrexate
- **DRUG:** thiotepa
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00621036
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-10-19
- **Primary completion:** 2008-12-08
- **Final completion:** 2008-12-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** MyVax did not meet its primary endpoints
- **Last updated:** 2018-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621036, "Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00621036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*